CompanyGraph
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
300401 · SZSE · China
hybiotech.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.34B, above the global median of $1.18B
- FinancialsAltman Z-Score 3.69: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.69%Below 5Y avg (0.92%)
Annual Rate
CNY 0.11Paid annual
Payout Ratio
24.6%Sustainable
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.96BCNY1.34B · vs all stocks (USD)
Trailing P/E
35.76xRevenue (TTM)
1.29BCNY193.11M · vs all stocks (USD)
Profit Margin
21.27%Beta
0.4620xvs all stocks
52-Week Change
16.50%vs all stocks
Market Capitalization
8.96BCNY1.34B · vs all stocks (USD)
Enterprise Value
9.25BCNY1.38B · vs all stocks (USD)
Trailing P/E
35.76xForward P/E
20.31xPrice to Sales (TTM)
6.93xPrice to Book (MRQ)
2.51xEnterprise to Revenue
7.15xEnterprise to EBITDA
17.68xGross Margin
42.84%Profit Margin
21.27%Operating Margin
23.61%Return on Assets (TTM)
3.66%Return on Equity (TTM)
7.95%Revenue (TTM)
1.29BCNY193.11M · vs all stocks (USD)
Revenue per Share (TTM)
2.35CNYUpdated Sep 20, 2026Quarterly Revenue Growth
34.40%Gross Profit (TTM)
641.55MCNY95.73M · vs all stocks (USD)
EBITDA (TTM)
342.37MCNY51.09M · vs all stocks (USD)
Net Income (TTM)
275.24MCNY41.07M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
25.60%Operating Cash Flow (TTM)
394.60MCNY58.88M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-75.83MCNY-11.32M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1130CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.69%vs all stocks
5-Year Average Dividend Yield
0.92%vs all stocks
Payout Ratio
24.57%Minority Interest (Equity)
-10.13KCNYFY2025 · Dec 31, 2025Revenue
1.24BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
549.06MCNYFY2025 · Dec 31, 2025Gross Profit
688.34MCNYFY2025 · Dec 31, 2025Operating Income
383.03MCNY57.16M · vs all stocks (USD)
Pre-tax Income
352.50MCNYFY2025 · Dec 31, 2025Income Tax Expense
47.64MCNYFY2025 · Dec 31, 2025Net Income
304.86MCNYFY2025 · Dec 31, 2025EBIT
384.97MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
571.39MCNYFY2025 · Dec 31, 2025Research & Development
65.46MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
149.90MCNYFY2025 · Dec 31, 2025Other Operating Expenses
25.40MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.24MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
32.47MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5600CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
544.40MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
544.40MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
304.86MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
6.32KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
293.81MCNYFY2025 · Dec 31, 2025Free Cash Flow
-67.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
924.32MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
304.86MCNYFY2025 · Dec 31, 2025Other Non-cash Items
31.94MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-132.19MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
89.20MCNYFY2025 · Dec 31, 2025Capital Expenditures
-361.02MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.75BCNYFY2025 · Dec 31, 2025Sale of Investments
1.50BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-610.16MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.13BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.15BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-92.15MCNYFY2025 · Dec 31, 2025Other Financing Charges
-90.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-208.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
544.82MSharesUpdated Sep 20, 2026Float Shares
359.89MSharesUpdated Sep 20, 2026% Held by Insiders
34.73%vs all stocks
% Held by Institutions
8.39%vs all stocks
Total Cash (MRQ)
1.37BCNY204.10M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.51CNYUpdated Sep 20, 2026Total Debt (MRQ)
1.84BCNY274.31M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5141xCurrent Ratio (MRQ)
2.18xBook Value per Share (MRQ)
6.56CNYUpdated Sep 20, 2026Total Assets
5.78BCNY862.76M · vs all stocks (USD)
Total Current Assets
2.42BCNYFY2025 · Dec 31, 2025Total Liabilities
2.29BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.37BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.33BCNYFY2025 · Dec 31, 2025Total Current Liabilities
958.12MCNYFY2025 · Dec 31, 2025Cash
924.32MCNYFY2025 · Dec 31, 2025Cash Equivalents
108.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.03BCNYFY2025 · Dec 31, 2025Other Short-term Investments
301.22MCNYFY2025 · Dec 31, 2025Accounts Receivable
224.30MCNYFY2025 · Dec 31, 2025Inventory
750.08MCNYFY2025 · Dec 31, 2025Accounts Payable
328.88MCNYFY2025 · Dec 31, 2025Short-term Debt
491.43MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.04MCNYFY2025 · Dec 31, 2025Long-term Debt
1.26BCNYFY2025 · Dec 31, 2025Common Stock (Book)
543.47MCNYFY2025 · Dec 31, 2025Retained Earnings
2.50BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.49BCNY520.64M · vs all stocks (USD)
52-Week Low
10.68CNYUpdated Sep 20, 202652-Week High
23.44CNYUpdated Sep 20, 202652-Week Change
16.50%vs all stocks
Beta
0.4620xvs all stocks
50-Day MA
14.38CNYUpdated Sep 20, 2026200-Day MA
15.24CNYUpdated Sep 20, 2026Avg 10-Day Volume
25.60MSharesUpdated Sep 20, 2026Avg 30-Day Volume
31.01MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.4600CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.69: safe zoneNotable
Altman Z-Score: 3.69
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.34B, above the global median of $1.18BNotable
Market cap (USD): 1,337,344,462.875Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule